Pharmaceutical Information |
Drug Name |
Levobunolol |
Drug ID |
BADD_D01267 |
Description |
A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma. |
Indications and Usage |
For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension. |
Marketing Status |
approved |
ATC Code |
S01ED03 |
DrugBank ID |
DB01210
|
KEGG ID |
D08115
|
MeSH ID |
D002040
|
PubChem ID |
39468
|
TTD Drug ID |
D00IUG
|
NDC Product Code |
Not Available |
UNII |
G6317AOI7K
|
Synonyms |
Levobunolol | Apo-Levobunolol | Apo Levobunolol | ApoLevobunolol | Betagan | Levobunolol Hydrochloride | Novo-Levobunolol | Novo Levobunolol | NovoLevobunolol | W-7000A | W 7000A | W7000A | ratio-Levobunolol | ratio Levobunolol | Ultracortenol | Vistagan | AKBeta | PMS-Levobunolol | PMS Levobunolol | PMSLevobunolol |
|
Chemical Information |
Molecular Formula |
C17H25NO3 |
CAS Registry Number |
47141-42-4 |
SMILES |
CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|